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This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre over the period Nov 2015 to April 2016 to 
inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The LVIF is a 
seven-and-a-half year, CA$57 million partnership between the Bill & Melinda Gates 
Foundation, Global Affairs Canada and Canada’s International Development Research 
Centre. It focuses on those animal diseases posing the greatest risk to poor livestock 
keepers in Sub-Saharan Africa, South and Southeast Asia, targeting transboundary 
diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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ACIAR  Australian Center for International Agricultural Research 
AI  Avian influenza 
APMV  Avian paramyxovirus 
AU  African Union 
AU-IBAR African Union InterAfrican Bureau For Animal Resources 
AU PANVAC AU Pan African Veterinary Vaccine Centre 
BSL-3  Biosafety level 3 (Laboratory designation required for challenge studies) 
DIVA   Differentiating infected from vaccinated animals (strategy) 
ELISA  Enzyme-linked immunosorbent assay 
FAO  Food and Agriculture Organization of the United Nations 
H  Hemagglutinin  
HA  Hemagglutinin antigen 
HI  Hemagglutinin inhibition 
HN  Hemagglutinin-neuraminidase 
I-2  Thermostable live Newcastle disease vaccine  
IB  Infectious bronchitis 
IBD  Infectious bursal disease 
IDRC  International Development Research Centre 
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ILT  Infectious laryngotracheitis 
HPAI  Highly pathogenic avian influenza 
ICPI  Intracerebral pathogenicity index 
LBM  Live bird market 
LPAI  Low pathogenic avian influenza 
LVIF  Livestock Vaccine Innovation Fund 
MAbs  Monoclonal antibodies 
NDV  Newcastle disease virus 
NA  Neuraminidase 
NI  Neuraminidase inhibition 
NIH  National Institute of Health (U.S. Government) 
OIE  World Organization for Animal Health 
RT-PCR  Reverse transcription polymerase chain reaction 
SEPRL  Southeast Poultry Research Laboratory (U.S. Government) 
SPF  Specific pathogen free 
USA  United States of America 
USD/US$ United States Dollars 
V4  Thermostable live Newcastle disease vaccine 
VI  Virus isolation 
VN  Virus neutralization 
WAHID  Interface for the World Animal Health Information System  
WAHIS  World Animal Health Information System (database) 
WHO  World Health Organization  
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NDV is a single stranded, double enveloped RNA virus belonging to the Order Mononegavirales, Family 
Paramyxoviridae [1].  The NDV is composed of 6 structural proteins: nucleocapsid protein (N); phosphoprotein 
(P); matrix (M); fusion (F); hemagglutinin--neuraminidase (HN); and the RNA-dependent RNA polymerase (RNAP) 
designated the large polymerase (L).  The host protein actin, also is incorporated into virus particles and is used 
for virus entry [1].  NDV viruses are classified into pathotypes, with increasing severity: asymptomatic enteric 
based, lentogenic, mesogenic, and velogenic based on an experimental chicken challenge model.  Velogenic NDV 
is considered by the OIE as reportable and are further characterized as either neurotropic or viscerotropic based 
on clinical and pathological features.  Clinical signs vary depending on: virus virulence; dose; route of 
transmission (respiratory is fastest); host species; breed; age; host immune status (exposure and vaccination 
history); and other factors.  A recent study assessing the F protein from 1,995 GenBank submissions revealed 
that class I viruses primarily affecting wild birds comprise a single genotype, while class II contains 15 genetic 
groups.  The official incubation period of NDV defined by the OIE is 21 days however the biological incubation 
period is between 2-15 days, with most cases occurring within 5-6 days following exposure but possibly as long 
as 3-4 weeks.  Species susceptibility in decreasing order are as follows: chickens, turkeys, pheasants, pigeons and 
ducks.  The preferred method of diagnosis is virus isolation and subsequent characterization [2]. 
NDV is considered the most significant cause of poultry losses globally and has been reported on 6 of the 7 
continents of the earth [1].  The economic impact of Newcastle disease in terms of lost livestock units between 
2006-2009 was greatest in South Asia and Viet Nam [21]. Mesogenic NDV is endemic in Africa, Asia, Central and 
South America and the Middle East while lentogenic strains are found in all 6 inhabited continents.  Wild birds 
are the reservoir for NDV in poultry.  Commercial poultry that are vaccinated are also potential carriers of live 
NDV vaccine strains, which can affect smallholder populations at the interface of commercial and smallholder 
poultry.  Velogenic NDV is endemic in areas of Mexico, Central and South America, widely spread in Asia, the 
Middle East and Africa, and in double-crested wild cormorants in the US and Canada [2].  From a total of 21,370 
NDV events reported in 20 selected countries between 2000 and 2015, at least 5,290 (25%) NDV disease events 
were reported from 14 selected African countries and 16,080 (75%) NDV disease events were reported from 6 
selected Asian countries.  Reporting bias must be considered when interpreting these estimates.  NDV 
mesogenic and velogenic pathotypes persist in all Asian countries.   
The application of biosecurity remains challenging in smallholder settings, while marketing interventions 
through the value chains hold more promise to improve prevention and control of NDV.  A shift away from the 
traditional production-based research is needed to a new approach that is market-driven and focused on trade 
and poverty alleviation. Including linkage with the private sector resources and skills [25].  There is no medical 
treatment for NDV, so vaccination remains an important means for both prevention and control of NDV in 
smallholder settings. 
The strategic objectives for an ideal vaccine and vaccination program include the following: 
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• Live prime dose that is safe and non-reverting to virulent form after it has circulated in live poultry; 
• Thermostable for ease of use in smallholder setting; 
• Protective, long-lasting immunity resulting in reduced replication and transmission on a population 
basis; 
• Vaccine is matched with the genotype of circulating field strains, ideally using reverse genetics 
technology [8][14]; 
• Can be delivered easily using simple and attainable field logistics; 
• Rapid onset and long duration of immunity; 
• Potential combination as part of a multivalent vaccine with other priority diseases for smallholders such 
as infectious bursal disease (IBD) based on country needs assessments. 
Key Conclusions Related to Vaccination are presented as follows: 
Short-term Solutions: Live, attenuated and killed, inactivated NDV vaccines are effective, and can produce 
protective titers when applied properly. The first approach would be to 1) improve disease detection using rapid 
test kits; 2) improve reporting; 3) and optimize the access and delivery of vaccines in the field since it is a limiting 
gap regardless of the vaccine that is used. Thermostable vaccines currently are closest to the ideal vaccine for 
use in smallholder poultry. Proper delivery of vaccine to smallholder with community engagement is a key gap 
to overcome logistical challenges for the safe and effective delivery of vaccine. 
Medium-term Solutions: 1) The further development of reverse genetics vaccines antigenically matched with the 
field strain genotype will optimize the immune response (level and duration of immunity) in typical currently 
available vaccine strains. Investment in the collection and molecular analysis of country-specific field strains will 
be required. 2) Improvement in diagnostic tests in vitro (cell culture) and rapid tests in the field will also be 
needed to replace the need for SPF poultry. 
Long-term Solutions: There are two main needs: 1) Further refinement of a vaccination model multivalent, non-
replicating, antigenically matched and epidemiologically appropriate; 2) Development of breed lines of native 
poultry with high levels of innate genetic resistance to further reduce virus replication and increase vaccine 
efficacy. 
The following gaps are highlighted in relation to vaccine development and sustainable field implementation of 
vaccination for Newcastle disease: 
• Lack of accurate information on reservoirs as well as NDV incidence and prevalence from farmers, 
including epidemiologically related semi-intensive poultry producers and the government services; 
• Limited genotype characterization of country-specific field strains of NDV. 
• Need for field based rapid test kits to detect the field strains since no field based test kits are currently 
available;  
• Need to replace the SPF chicken challenge based model with a cell line culture model in developing 
countries with laboratories lacking BSL-3 required to conduct challenge studies safely; 
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• Systematic delivery and monitoring of vaccine use so that it is applied uniformly among members of 
smallholder village flocks;   
• Wider application of safe, non-replicating NDV vaccines at the interface of commercial and smallholder 
sectors where spillover can occur.  
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In 1926 the first reported outbreaks of Newcastle 
disease occurred in Java, Indonesia, and Newcastle-
upon-Tyne, England (also known as peudo-fowl pest; 
exotic Newcastle disease; and Ranikhet disease). NDV 
is a single stranded, double enveloped RNA virus 
belonging to the Order Mononegavirales, Family 
Paramyxoviridae.  NDV belongs to the subfamily 
Paramyxovirinae that includes Rubulavirus, which 
includes human mumps virus; Respiroviruses, 
containing mammalian parainfluenza 1 and 3; 
Morbillivirus, which includes canine distemper, 
rinderpest, and measles; Henipavirus, containing 
Nipah and Hendra virus; and the Avulavirus genus 
that contains NDV and other APMV [1].  
NDV is a hemagglutinating virus like AI virus. The HN 
protein binds to host red blood cells while NA protein 
is associated with both entry and efficient viral 
release from host cells, in conjunction with F protein.  
Cell fusion and hemolysis is mediated by F protein, 
which is cleaved by host protease enzymes to form F1 
and F2 by products.  
There are 11 APMV serotypes, and APMV-1 is the 
most important for poultry, including NDV.  The 
nomenclature for APMV is similar to the one for AI 
virus.  A summary of APMV serotypes is presented in 
Table 1 [1].  
Virus structure 
The NDV is composed of 6 structural proteins: 
nucleocapsid protein (N); phosphoprotein (P); matrix (M); 
fusion (F); hemagglutinin--neuraminidase (HN); and the 
RNA-dependent RNA polymerase (RNAP) designated the 
large polymerase (L).  The host protein actin, also is 




Figure 1: Schematic structural components of a 
Newcastle disease virion 
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NDV viruses are classified into pathotypes, with increasing severity: asymptomatic enteric, lentogenic, 
mesogenic, and velogenic based on an experimental chicken challenge model. Velogenic NDV is considered by 
the OIE as reportable and velogenic pathotypes are further characterized as either neurotropic or viscerotropic 
based on clinical and pathological features.  
Newcastle disease is defined as an infection of birds caused by APMV-1 (serotype 1) as follows [1][2]: 
1. The virus has an intracerebral pathogenicity index (ICPI) in day old chicks of 0.7 or greater; or 
2. The virus has multiple basic amino acids (3 lysine or arginine residues between 113-116 residue positions) at 
the C-terminus of the F2 protein and phenylalanine at residue 117 of the N-terminus of F1 protein. The 
absence of basic amino acid residues also requires the ICPI test. 
 
 
Table 1: Prototype avian paramyxoviruses with host range [1]. 
 
APMV group with prototype strain Natural hosts Other hosts Disease 
APMV-1 NDV Many Velogenic NDV 
in N. American 
cormorant  
Mild to severe; rare 
in wild birds 
Pigeons (PPMV-1) Chickens  Mild to severe 
APMV-2 /chicken/California/Yucaipa/56 Turkey, passerine Chicken, 
psittacine, rails 
Mild; egg drop 
APMV-3/turkey/Wisconsin/68 Turkey None Mild; egg drop 
APMV-4/duck/Hong Kong/D3/75 Ducks Geese None known 
APMV-5 /budgerigar/Japan/Kunitachi/74 Budgerigars None known Not in poultry 
APMV-6/duck/Hong Kong/199/77 Ducks Geese, rails, 
turkeys 
None ducks and 
geese; moderate in 
turkeys 
APMV-7/dove/Tennessee/4/75 Pigeons, doves Turkey, ostrich Mild in turkeys 
APMV-8/goose/Delaware/1053/76 Ducks and geese None known Not in poultry 
APMV-9/domestic duck/New York/22/78 Ducks None known Asymptomatic 
infection in ducks 
APMV-10/Rock Hopper/Falkland Islands/324/2007 Rock Hopper penguin Magellanic 
penguins 
Not in poultry 
APMV-11/Common Snipe/France/100212/2010 Common snipe None known Not in poultry 
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NDV has been reported on 6 of the 7 continents of the earth.  Mesogenic NDV is endemic in Africa, Asia, Central 
and South America and the Middle East while lentogenic strains are found in all 6 continents noted previously.  
Velogenic NDV is endemic in areas of Mexico, Central and South America, widely spread in Asia, the Middle East 
and Africa, and in double-crested wild cormorants in the US and Canada [3][4]. Between 2005 and 2015 NDV was 
reported to the OIE at least once in 121 countries globally [4]. Lentogenic strains of NDV are worldwide in their 
distribution. Mesogenic pathotypes with a special adaptation to pigeons (i.e. pigeon paramyxovirus) do not 
appear to infect other poultry readily [1][4]. Figures 2 and 3 demonstrate the global spatial (Figure 2) and 
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*Countries report every 6 months to OIE, hence 2015 reports are incomplete. 
 
Figure 3: Temporal distribution of NDV outbreaks reported to OIE 2000-2015 [6] 
 




Avirulent and virulent strains can be distinguished on the basis of the cleavage site sequence of the F protein. 
During replication, the fusion gene is translated into a pre-cursor protein, F0 that must be cleaved by host cell 
proteases into F1 and F2 subunits for the viral particles to become infectious.  
APMV-1 isolates are separated into two clades, called class I and class II, based on the genetic ancestral 
relationship among viruses. A clade is a group of viruses linked to a common ancestor.  Class I isolates have been 
found mainly in wild waterfowl, and are usually of low pathogenicity [7].  A recent study assessing the F protein 
from 1,995 GenBank submissions revealed that class I viruses comprise a single genotype, while class II contains 
15 genetic groups including 10 previously established (I–IX, and XI) and five new genotypes (X, XII, XIII, XIV and 
XV) using a unified nomenclature and more objective criteria (Table 2) [8].  
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Table 2: Criteria used to define Newcastle virus genotypes based on an analysis of 1,995 GenBank 
submissions [8] 
 
1 Genotype and sub-genotype designations were maintained as previously described when possible (i.e. genotype I remains I and sub-genotype Ia remains Ia)   
2 
New genotypes and sub-genotypes were assigned based on the phylogenetic tree topology using the 
Maximum Likelihood method and the optimum  nucleotide model (GTR +G +I) as determined by MEGA5. 
Phylogenetic tree topology was supported by the evolutionary distances between groups   
3 New genotypes or sub-genotypes were designated only when the complete F gene sequence of at least four independent isolates without a direct  epidemiologic link (i.e. distinct outbreaks) were available   
4 
The mean nucleotide distance (evolutionary distances) between and within groups was inferred as base 
substitutions per site by averaging all sequence pairs  with the MEGA5 software and the Maximum 
Composite Likelihood model   
5 
The mean interpopulational evolutionary distance (mean distance between genotypes) was estimated using 
the Maximum Composite Likelihood model  (0.106; standard error = 0.0061) and set as the cutoff value to 
assign new genotypes   
6 Different genotypes should have an average distance per site >10% (0.1). Different sub-genotypes should have an average distance per site between 3 (0.03)  and 10% (0.1)   




NDV demonstrate considerable drift due to transcription errors, however more recently recombination is 
considered to play a role in shaping the genetic structure of the APMV type 1 [7]. Progress made in recent 
reclassification should now be considered in relation to vaccine selection and the management of vaccination 
programs. The majority of NDV vaccines belong to genotypes I and II [8]. Figure 4 depicts the molecular groupings 
and relationships amongst the 15 NDV genotypes [8].  
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Figure 4: Phylogenetic analysis based on the complete nucleotide sequence of the F gene of viruses 
representing NDV class II [8] 
 
The global diversity of NDV genotypes and among and within countries is significant.  Genoptypes VII and VIII 
emerged in the 1960’s in South Africa, Europe and Asia and genotype VII is currently the predominant genotype 
found in Asia [9]. Viruses characterized in Mozambique in 2005 belonged to lineage Vb, a similar finding in 1995 
and can be concluded that no new introduction of the virus occurred from 1995 to 2005 in Mozambique [10]. 
Another recent study in Cameroon found that most strains were related to vaccine strains, but a single genotype 
XVII strain was also found. Only three highly similar genotype XVII strains were detected in the Central African 
Republic. Subgenotypes XVIIa, XVIIIa, and XVIIIb co-circulated in Côte d’Ivoire, while subgenotypes XIVa, XIVb, 
XVIIa, XVIIb, and XVIIIb were found in Nigeria [11]. A study conducted in Ethiopia indicated that the viruses are 
clustered together within the new sub-genotype VIf [12]. In Madagascar, the phylogenetic analysis of F gene from 
isolates resembles the “old” genotype IV but may be distant enough to constitute a new genotype, namely 
genotype XI (or lineage 3g) [13]. 
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The significant genomic diversity of NDV is enhanced by the large variety of avian species susceptible to NDV 
infection and the availability of highly mobile wild bird reservoirs. The genomic diversity of NDV increases the 
possibility of diagnostic failures and unidentified infections. Therefore, ongoing epidemiological surveillance and 
pro-active characterization of circulating strains is required to ensure that the vaccines and PCR reagents are 
effectively applied worldwide. Large phylogenetic and antigenic distances between vaccines and current 
circulating virulent strains may facilitate the evolution of virulent/velogenic NDV [14]. Discussion of NDV 
pathotypes is considered below under NDV diagnosis. 
 
Host Factors 
NDV is shed from infected birds in a number of ways via: i) oropharyngeal secretions and cloacal excretions; ii) 
vertically transmitted through via infected eggs; and iii) inapparent (chronic) carriers (shedders) first exposed to 
lentogenic and/or subsequently exposed to a velogenic strains. Flies may also act as mechanical and possibly as 
biological vectors [7]. Transmission can then occur by direct contact with feces and respiratory discharges or by 
contaminated food, water, equipment, and human clothing. Humans act as ideal mechanical vectors and can be 
an end host with mild to severe conjunctivitis following exposure natural or vaccine strains of NDV [1][7][14].   
The interface between wild bird reservoirs and poultry is key to understanding the epidemiology of NDV viruses.  
NDV has been documented in 241 avian species [1]. Virus is shed during the incubation period and for a short 
time during recovery. Birds in the pigeon family can shed the virus intermittently for a year or more. Other wild 
birds such as cormorants have also been associated with outbreaks in domestic poultry. Wild waterfowl and 
shorebirds are infected with a large and diverse group of avirulent viruses that normally do not produce any 
clinical signs in poultry (class I). Almost half of the class I viruses found in the United States originate from the 
Mallard duck (Anas platyrhynchos) with six class I genotypes represented, suggesting that certain species are 
highly susceptible to NDV infection and likely to be reservoirs [14]. Spillover of class I NDV from wild birds to 
poultry does occur and these avirulent viruses have the potential to become virulent over time by:  i) gaining 
basic amino acids near the F protein cleavage site; ii) transmission from large mobile populations of wild birds; 
and iii) escape of live vaccine strains from poultry farms into the wild bird environment [14]. Although the most 
likely reservoir of velogenic NDV is the vaccinated poultry population there is evidence that wild birds may 
represent natural reservoirs of mesogenic viruses, some of which are used as vaccine strains [1].  
Low virulence class I and mesogenic viruses of class II and genotypes V or VI predominate in cormorants and 
pigeons.  In contrast the viscerotropic velogenic NDV are predominant in vaccinated poultry, suggesting that the 
immune pressure from vaccination may be selecting variant forms of velogenic NDV. The persistence of 
velogenic NDV in poultry despite intensive vaccination efforts has been a recurrent phenomenon in endemic 
countries of Asia, Africa and Central America [14].  Genetic homogeneity (intensive poultry production), high-
density rearing (increasing the number of “effective contacts”), and intensive vaccination programs may be 
contributing to the evolution of virulent NDV [14].  Epidemiological and value chain links at the interface between 
smallholders, intensive poultry production and wild birds should be considered prior to embarking on a 
vaccination program. 
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Following removal of organic matter, NDV is susceptible to 1% phenol or quaternary ammonium disinfectants; 
ultraviolet light, acidic hydrogen based chemical agents (e.g. Virkon).  NDVes can survive for several weeks in the 
environment, especially in cool weather.   
A meta-analysis of epidemiological studies conducted in Africa between 1980 and 2009 has identified 
environmental (Figure 5) and seasonal correlations with the occurrence of NDV. The study found country 









In general, NDV is most common encountered during dry winter months in Southeast Asia, and generally also 
the dry season in African countries (Figure 6) [15].   
Exposure and seroconversion is greater in backyard village than commercially raised poultry, likely due to 
housing and accessibility of wild birds [15]. Human movement, cultural practices, marketing and poultry 
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vaccinators are also important risk factors for transmission and spread of NDV [15].  Value chains play an 
important environmental risk for exposure.  Studies in Mali, Ethiopia and Madagascar highlight the importance 
of trade and attendance at a market and the vicinity of traders are correlated to a higher prevalence of NDV 
virus on farms [12][13][16]. In Madagascar, the risk of infection at the district level is statistically related to the 
density of trade flows. Similarly, the risk of virus circulation increases in markets because of the high density of 




Figure 6: Meta Meta-analysis of NDV seasonality related to outbreaks and vaccination from studies 
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Clinical signs vary depending on: virus virulence; dose; route of transmission (respiratory is fastest); host species; 
breed; age; host immune status (exposure and vaccination history); and other factors.  The official incubation 
period for OIE is 21 days however the biological incubation period is between 2-15 days, with most cases 
occurring within 5-6 days following exposure but possibly as long as 3-4 weeks.  Species susceptibility in 
decreasing order to NDV is as follows: chickens, turkeys, pheasants, pigeons and ducks.  The main clinical signs 
are as follows [1]: 
1. Viscerotropic velogenic NDV  
a. Unvaccinated chickens: Listlessness, severe lethargy and 100% mortality within 3-4 days; following 
ocular nasal transmission: bilateral conjunctivitis, severe swelling of eyes, combs, wattles, clear 
mucus exuding from the mouth, drooping head and green watery diarrhea;  
b. Vaccinated chickens: drop in egg production with misshapen or bleached eggs one month after 
infection.  
 
2. Neurotropic velogenic NDV  
a. Unvaccinated chickens: Excitability during the first 3-4 days followed by tremors, torticollis, and 
paralysis of one wing or leg and failure to access feed and water with death after 9 days; 50% 
mortality in older birds but higher in young birds; 
b. Chicken isolates can cause neurological signs in pigeons. 
 
3. Mesogenic NDV strains in unvaccinated chickens: tremors, torticollis, and paralysis but limited mortality; 
pigeon isolates may lead to asymptomatic infections. 
 
4. Lentogenic NDV: no clinical signs in adults, but naïve unvaccinated birds or birds vaccinated with live La Sota 
strain can show respiratory signs: mild to serious respiratory distress.  Note:  Poor vaccination technique can 
result in incomplete vaccination of flocks and a “rolling reaction” whereby replication, amplification and host 




“The severity of disease produced varies with both host and strain of virus. Even APMV-1 strains of low virulence 
may induce severe respiratory disease when exacerbated by the presence of other organisms or by adverse 
environmental conditions (ammonia). The preferred method of diagnosis is virus isolation and subsequent 
characterization” [2].   NDV is immunosuppressive and increases susceptibility to other viruses, bacteria and 
parasites [1].   
Differential Diagnosis 
The symptoms and pathology of NDV are not pathognomonic and the main differential diagnoses of NDV 
include LPAI and HPAI pathotypes, as well as aspergillosis, mycoplasmosis, ILT and IB [1]. 
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Lesions seen in birds will depend on their previous exposure to wild virus or to NDV vaccine.  In non-vaccinated 
or exposed birds the following gross lesions can be observed and the main clinical and pathological observations 





Table 3:  Main clinical and pathological features of viscerotropic velogenic (VV), neurotropic velogenic (NV), 
mesogenic (M), lentogenic (L) and asymptomatic (A) pathotypes in chickens. 
 
Clinical/Pathological Hallmarks VV NV M L A 
Hemorrhagic necrosis of diffuse lymphoid tissues of the intestine +++ +/- - - - 
Enlarged spleen +++ - - - - 
Hemorrhagic necrosis of laryngeal tonsils and upper trachea +++ - - - - 
Swelling of head, face, eyes +++ - - - - 
Hemorrhagic necrosis of comb, wattles and face +++ - - - - 
Egg yolk peritonitis +++ - - - - 
Mortality +++ +++ ++/+ + - 
Respiratory difficulty +++ +++ ++ + - 
Depression +++ +++ ++ +/- - 
Optisthotonus  +++ +/- - - 
Torticollis  +++ +/- - - 
Enteritis +++ - - - - 
No clinical/pathological signs - - - +/- +++ 
Legend:  Severe/High (+++); Moderate (++); Mild (=); None (-) 
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OIE Terrestrial Manual Chapter 2.3.14 outlines the following diagnostic tests for NDV [2]: Samples should be 
collected from recently dead birds or moribund birds that have been killed humanely. Identification of the agent 
is done as follows: 
• Dead birds: oro-nasal swabs; lung, kidneys, intestine (including contents), caecal tonsils, spleen, brain, 
liver and heart tissues, separately or as a pool;  
• Live birds: tracheal or oropharyngeal and cloacael swabs (visibly coated with faecal material) from live 
birds or from pools of organs and faeces from dead birds;   
• Special attention should be given to appropriate types of media for shipping  
 
Identification of NDV 
1. VI from inoculation of embryonated eggs. Samples from live birds should include both tracheal or 
oropharyngeal and cloacal swabs (collected and stored separately), the latter should be visibly coated with 
fecal material. Swabbing may harm small, delicate birds, but the collection of fresh feces may serve as an 
adequate alternative.   
2. HA activity detected from inoculated eggs may be due to the presence of any of the ten subtypes of APMV 
(including NDV) or 16 hemagglutinin subtypes of influenza A viruses, or. Nonsterile fluid could contain 
bacterial HA. NDV can be confirmed by the use of specific antiserum in a hemagglutination inhibition (HI) 
test. Usually chicken antiserum that has been prepared against one of the strains of NDV.  
3. ICPI: Fresh infective allantoic fluid with a HA titre >24 (>1/16) is diluted 1/10 in sterile isotonic saline with no 
 additives, such as antibiotics.  0.05 ml of the diluted virus is injected intracerebrally into each of ten chicks 
hatched from eggs from an SPF flock. These chicks must be over 24-hours and under 40-hours old at the time 
of inoculation.   ICPI is the mean score per bird per observation over the 8-day period.   
4. Molecular method: requirement of at least one pair of basic amino acids at residues 116 and 115 plus a 
phenylalanine at residue 117 and a basic amino acid (R) at 113 if the virus is to show virulence for chickens.   
Failure to detect virus or detection of NDV without multiple basic amino acids at the F0 cleavage site using 
molecular techniques does not confirm the absence of virulent virus and the ICPI must be performed.   
5. Monoclonal antibody panels have been developed. 
6. Phylogenetic studies [8]. 
7. RT-PCR with appropriate primers. 
 
Serological tests 
1. HA and HI tests  
2. ELISA kits are available and based on several different strategies for the detection of NDV antibodies, 
including indirect, sandwich and blocking or competitive ELISAs using MAbs. At least one kit uses a subunit 
antigen. Conventional ELISAs have the disadvantage that it is necessary to validate the test for each species 
of bird for which they are used. Competitive ELISAs may not recognize all strains of APMV-1 if they use 
Monoclonal Antibodies known for their specificity for single epitopes.  
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Although all APMV-1 viruses are of the same serotype, minor variations can be detected by using the VN test [1]. 
Many Asian countries (including India and Pakistan), rely of mesogenic strains to induce protective immunity in 
vaccinates to more virulent forms [1]. Ideally a useful vaccine will permit the ability to DIVA, particularly when the 
disease is rare.  This can be accomplished by designing a vaccine with a marker found in heterologous or subunit 




NDV is a zoonotic disease, which may result in mild conjunctivitis in humans.  Laboratory personnel, poultry 
owners, farm workers, and veterinarians who handle poultry are at highest risk.  Transmission can occur via 
infected oral, ocular and cloacal contents or via aerosol [1]. Immunosuppressed individuals are particularly 
vulnerable, however no person-to-person spread has been reported. 
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Although Newcastle disease is one of the most important diseases impacting the health of poultry and the 
health and livelihoods of the rural poor, it remains grossly under-reported globally [3][17].  It is estimated to be the 
7th leading cause of animal losses globally as expressed by livestock units presented in Tables 4 [21].   
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From a total of 21,370 NDV events reported in the 20 selected countries considered under the LVIF between 
2000 and 2015, about 5,290 (25%) NDV disease events were reported from 14 selected African countries and 
16,080 (75%) NDV disease events were reported from 6 selected Asian countries.  Reporting bias must be 
considered when interpreting these estimates. Mesogenic and velogenic NDV pathotypes occur in all Asian 
countries.  In 2014-2015, India recorded 311 outbreaks of NDV (Ranikhet) based mainly on passive surveillance 
[22].  A regional map of NDV reported for Africa in 2011 is presented in Figure 7 and NDV is reported the most 
commonly animal disease among all African countries [16]. The four countries with the highest number of 
reported ND outbreaks in Africa include Zambia (n=137), Ghana (n=127), South Africa (n=86) and Botswana 
(n=82).  
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Figure 7: Spatial distribution of NDV events reported in Africa during 2011. 
 
Tables 6 and 7 summarize the estimates of incidence and prevalence from NDV events reported and studies 
conducted, respectively in the 20 selected countries between 2000 and 2015. In Africa, the prevalence of NDV in 






2014 | Pan African Animal Resources Yearbook 31
Country Outbreak Susceptible Cases Deaths Slaughtered  Destroyed
South Sudan 20 195 155 72 52 0
Sudan 2 3267 2 1 0 0
Tanzania 11 56081 1431 971 0 0
The Gambia 6 206     
Togo 8 12055 1283 198 63 1082
Tunisia 24 245414 64388 42259 2730 0
Zambia 137 171145 50304 10921 0 0
Zimbabwe 65 42442 4981 4540 0 0
Total 797 3871149 701703 484911 4370 324511
Although the highest number of outbreaks was 
reported in October (12.8%), ND occurred 
throughout the year  without significa nt  monthly 
varia ility and temporal pattern.  This may point 
to  the lack of seasonality for the risk factors that 
underpin the occurrence and maintenance of the 
disease (Chart 9).
Map 9: Spatial distribution of ND during 2011
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Table 6: Incidence of Newcastle disease outbreaks in 20 selected countries, 2000-2015. 
 
Region/Country 
Reported Incidence NDV (OIE, WAHID) 
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail# (Accessed 20 October 2015) 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Sub Saharan Africa                
Burkina Faso 6 11 4 2 8 11 10 54 25 75 126 66 27 15 60 
Ethiopia 8 34 67 16 40 70 84 28 29 35 84 68 40+ 150 50 
Ivory Coast … … … … … ?+ 0 …+ 3 8 19+ 7 8 8 6 
Kenya 5 11 10 2 3 1+() 63 6 1 ? 19+ 2+ 7 2 9 
Madagascar 55 … 83 47 24 13 16 4+ …+ …+ 10 4 5 14 8 
Malawi 36 … 12 6 … 1 1+ 2 …+ …+ 2 3 10 5 … 
Mali 1 0 0 0 0 …+ 3 ? 2? 14 8 4 0 1 1 
Mozambique 3 9 6 7 15 12 5 4 5 2+ 4 2+ 6 4 3 
Rwanda … … … … 0 … 36 13 68+ 30? …+ … …+ 17 … 
Senegal 2 1 17 4 2 1 4 4 1 3 2 2 …+ 2 2+ 
South Africa 9 4 2 4 4 175 126 66 64 17 27 22 25 47 97 
Tanzania 40 49 126 147 57 91 44 129 34 25 25 17 14 10 10 
Uganda 58 110 103 86 53 9 1+ …+ …+ …+ …+ …+ … …+ …+ 
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Zambia 36 17 63 43 60 … 40 79 136 162 152 …+ 68 177 171 
South Asia                
Bangladesh …+ …+ …+ …+ …+ …+ …+ …+ …+ …+ …+ …+ …+ …+ … 
India 464 633 812 338 323 391 391 280 230 389 497 886 645 423 311 
Nepal 261 211 190 135 48 147 87 46 16+ 128 210 275 312 132 92 
Southeast Asia                
Indonesia … … … … … …+ …+ …+ …+ …+ …+ …+ …+ …+ … 
Myanmar 74 151 119 64 87 …+ 43 75 29 35 14 7 14 10 7 
Vietnam 134 … … 47 … 114 807 1174 1156 928 1181 180 94 77 70 
 
WAHIS Codes 2005-2015 
[ ... -  No information available for this disease; 0 - Disease absent; ? - Disease suspected; ? + - Infection/infestation; ...+ - Disease present but 
without quantitative data; + - Disease present with quantitative data but with an unknown number of outbreaks; +() - Disease limited to one or 
more zones ] 
HandiStatus II Codes 2000-2004: 
[ 0 - Disease never reported; ? - Disease suspected but presence not confirmed; …+ - Reported present or known to be present; … -  No 
information available]
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Table 7: Prevalence estimates of NDV in 20 selected countries. 
 
Region/Country Apparent Prevalence (95% CI) Study Design Time Period Reference 
Sub Saharan Africa 
    
Burkina Faso 13.8% (39/283) samples positive Active surveillance in outbreak 
areas 
2006 Tamagda et al, 2011 
Ethiopia 0.70% Cross-sectional serosurvey 2011-2012 Betteridge, 2014 
 
30.1% virus positive Cross sectional live bird market 
survey 
2012 Mulisa et al, 2014 
Ivory Coast 19.80% Active prospective backyard 
serosurvey  
2007-2009  Couacy-Hymann, 2012a 
0.3-1.4% Active, prospective, live market and 
backyard flock virus surveillance 
2009-2010 Couacy-Hymann, 2012b 
22% seropositive; 14.7% virus positive Active, prospective, live market and 
backyard flock virus surveillance 
2010-2012 Kouaku, 2015 
Virus prevalence of 15% in 2006 to 2008 
compared to prevalence of 0.3 to 1.4% in 2010  
In Ivory Coast, only sick birds were 
sampled 
2006-2011 Snoeck et al, 2013 
Kenya NDV higher (17.8%) in the dry hot zone (lower 
midland 5) compared to the cool wet zone 
(lower highland 1) at 9.9%  
Free range chicken farms NA Njagi, et al, 2010 
Madagascar Seroprevalence of 60% (non-vaccinated 
animals, (CI 95 57–63%), n = 778) 
Cross-sectional serological study 2008 Andriamanivo et al, 
2012 
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Region/Country Apparent Prevalence (95% CI) Study Design Time Period Reference 
Malawi 
    
Mali ND seroprevalence was 58.4%, and the odds of 
seropositivity was 2.0 higher in chickens than in 
ducks, 1.7 higher in females than in males, 3.1 
higher in adults than in young birds; NDV virus 
prevalence of 2.6% 
Prospective serosurvey among 
1470  
2007-2008 Molia et al, 2011 
Mozambique 66 percent of households who raised chickens 
had losses due to NDV 
TIA National Agricultural Survey 2005-2006 Tomo, 2009 
Rwanda 
    
Senegal Seroprevalence was 54.4% in rural chickens Prospective serosurvey of rural 
poultry 
2008 Kone et al, 2013 
South Africa 
    
Tanzania The highest seroprevalence (81.5) and virus 
isolation frequency (18/27) were found in the 
period between June and October 
Retrospective data and prospective 
cross sectional study 
Since 1994 Yongolo, 1996 
Uganda 80.4% of households had lost chickens Baseline KAP study  2003 Mbabazi, 2012 
Zambia Seroprevalence of NDV) in chickens in Zambia 
was 36.9% based on HI titres of 2000 blood 
samples 
Seroprevalence based on 2000 
samples 
NA Alders et al, 1994 
South Asia 
    
Bangladesh 7.5% of 1653 dead or sick bird laboratory 
submissions 
Retrospective secondary data 
analysis 
1999-2000 Giasuddin et al, 2002 
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Region/Country Apparent Prevalence (95% CI) Study Design Time Period Reference 
India 
    
Nepal 
    
Southeast Asia 
    
Indonesia 
    
Myanmar Median month-specific, village-specific 
mortality rates per 1000 bird-days at risk 
(counting missing birds as deaths) ranged from 
0.8 to 1.7 for adults, from 0.4 to 4.7 for growers 
and from 8.0 to 16.5 for chicks 
Longitudinal study to describe 
temporal patterns of mortality of 
village chickens in 10 villages in 
Myanmar. 
2003-2004 Henning et al, 2008 
Vietnam Seroprevalence of NDV- antibody titers (> log2 
3) was 47.7% (n = 81) 
Prospective serosurvey NA Vui et al, 2002 
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Conclusions from incidence and prevalence data 
It can be assumed that country reports are largely representing velogenic and mesogenic pathotypes.  This 
assumption is supported by data from Bangladesh where a 7.5% prevalence estimate was obtained from 
laboratory data that is gathered passively from voluntary submissions, despite no official incidence reporting to 
the OIE.   Another confounding issue is that viruses are rarely pathotyped, further affecting the accuracy of the 
estimates, since lentogenic NDV are ubiquitous and very common due to natural incidence or escape of live 
lentogenic vaccine strains used (e.g. La Sota).  NDV is a disease, which poultry owners expect and accommodate 
to each year and therefore underreporting is generally accepted in both Asia and Africa.  In terms of reported 
incidence Figure 8 depicts the ordered number of reports received, which reflect both incidence and reporting 
intensity.  Incidence data from the OIE is useful to show relative trends in reporting and qualitative estimates 
among the selected countries (Figure 8).  
 
Prevalence data reflect the methodologies used. LBM surveys are economical and easy to conduct as an initial 
scanning, targeted surveillance.  Household surveys are useful but costly to conduct however they give an 
accurate local estimate for a vaccination program and are more reliable to assess the initial risk as well as the 
impact of both NDV itself and a vaccination program.  Development and implementation of a vaccination 
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Economic and Social Impacts at Global 







Figure 9 summarizes the relationship between farmer income (log scale) and exposure risk (impact probability) 
to NDV at the regional level [19].  South Asia, sub-Saharan Africa and Southeast Asia rank as the top three most 
impacted regions globally.  This figure suggests that Newcastle disease is endemic in South Asia and sub-Saharan 
Africa, where smallholder poultry represents nearly 80% of the total poultry holders, while recurrent epidemics 
occur in regions with a mix of intensive and extensive poultry production. The intensive poultry producers of 
Australasia and North America maintained Newcastle disease-free status, as did the Island States of Oceania.  
Underreporting played a role, as was most likely the case for Central Asia [20].   Poultry provide animal protein in 
the form of meat and eggs and can be sold or bartered to meet essential family needs. Village poultry are active 
in pest control, provide manure, are required for special festivals and are essential for many traditional 
ceremonies.  They are generally owned and managed by women and children and are often essential elements 
of female-headed households [20].  The economic impact of Newcastle disease among selected countries in terms 
of lost livestock units between 2006-2009 was greatest in South Asia and Viet Nam as demonstrated in Figure 10 
[21]. 
The costs of NDV epidemics include lost production, lost trade and disease control [23]. In Bangladesh, a 
successful production model has been developed which involved more than 2 million women (households). This 
model has a structured approach to improve smallholder poultry production and health, and socio-economic 
development at village level Error! Reference source not found.].  For smallholder vaccine programs to be s
uccessful and sustainable, communities must take responsibility and be empowered to develop and implement 
solutions that meet the local needs.  Similarly, there is a need to initiate a major shift away from the traditional 
production-based research to a new approach that is market-driven, focused on trade and poverty alleviation. 
This shift must include a more effective linkage with the private sector and their resources and skills [25].  
For such an important disease affecting rural households globally, relatively little quantitative microeconomic 
information is available specific to Newcastle disease.  Studies estimating the qualitative social and economic 
impact of Newcastle disease related to the 20 selected countries are summarized below in Table 8.
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Figure 9: Relationship between farmer income (log scale) and exposure risk (impact probability) to NDV at 





Figure 10: Relationship between farmer income (log scale) and exposure risk (impact probability) to NDV at 
the regional level [21] 
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Table 8: Socioeconomic impact of Newcastle disease in 20 selected countries 
 
Region/Country Economic Impact Social Impact Reference 
Sub Saharan Africa 
   
Burkina Faso A survey achieved in 1998 in the project area revealed 
that the mortality rate were between 13-90% for 




   
Ivory Coast 
   
Kenya 
   
Madagascar 
   
Malawi 
   
Mali 
   
Mozambique In the south of Mozambique, women have been able to 
sell excess chickens in order to buy goats and eventually 
cattle 
Decreased chicken numbers, increased household 
purchasing power, increased home consumption 
of chicken products and increased decision-
making power for women 
Alders and Pym, 
2009 
Decreased access to cash or goods through exchange, 
but it also represents the possibility of gaining access to 
a good meal of higher nutritional value, and improved 
 
Bagnol, 2001 
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food security; 50 to 100 percent of deaths annually in 
rural households 
Rwanda 
   
Senegal 
   
South Africa 
   
Tanzania 
 
Increased chicken numbers, increased household 
purchasing power, increased home consumption 
of chicken products and increased decision-
making power for women 
Alders and Pym, 
2009 
Of the approximately 30 million chickens kept in 
Tanzania, 28 million are free-range village chickens [1]. 
They provide livelihood and supply 100% of eggs and 
chicken meat consumed in rural areas, where 83% of the 
population lives. In addition, they cater for 20% of the 
chicken egg and meat demand of urban consumers [2]. 
Free-range chickens have an important role in economic 
and nutritional needs of the Tanzanian people. 
 
Yongolo et al, 1996 
Uganda 
   
Zambia 
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Impact studies have demonstrated that income 
from the sale of eggs in South Asia is used to 
educate children. 
Alders, 2009 
Bangladesh 30% annual poultry losses at household level due to 
NDV 
 
Giasuddin et al, 
2002 
India 
   
Nepal 
   
Southeast Asia 
   
Indonesia 
   
Myanmar 
   
Vietnam Qualitative assessment: Newcastle disease is the most 
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There is no medical treatment for NDV in poultry.  Sanitary control measures are similar to those for AI including 
the following: 
Sanitary Control Methods 
Table 9 summarizes control measures recommended by the OIE (left column) with feasibility assessments in 
smallholder poultry settings [3]. 
Table 9: Feasibility of OIE recommended sanitary control measures in smallholder poultry settings. 
 
Sanitary Control Measures Feasibility in Smallholder Setting 
Movement Controls Limited: due to continual mixing and marketing of poultry 
Aggressive active surveillance Variable depending on technical capacity and cooperation 
Biosecurity measures Limited:  isolate, clean and disinfect, dispose of carcasses 
Culling 
Limited:  human habit of eating sick and dead poultry and rarely a policy 
option in developing countries unless trade is important 
Vaccination Possible during an outbreak but not advised (see next point) 
Training Vaccinators and animal health officials can spread disease 
Risk communication High if village leaders are engaged 
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Sanitary Prophylaxis  
Table 10 summarizes measures are recommended by the OIE (left column) with feasibility assessments in 
smallholder poultry settings [3]. 
 
Table 10: Feasibility of OIE recommended sanitary prevention measures in smallholder poultry settings 
 
Sanitary Prevention Measures Feasibility in Smallholder Setting 
Bird-proofing houses, feed and water supplies Limited: for feral poultry; Moderate for confined village 
poultry 
Proper carcass disposal Variable depending on food security needs 
Pest control in flocks; insects and mice  Limited: to confined village poultry 
Avoidance of contact with birds of unknown health 
status  
Limited: constant animal and human movement driven by 
an economic incentive 
Control of human traffic Limited: (see above) 
Control of vehicular traffic Limited: (see above) 
Quarantines and movement controls Limited: (see above) 
Thorough cleaning and disinfection of the premises 21 
days before restocking  
Limited: contaminated ground cannot be sterilized; 
Moderate for confined village poultry 
 
 
In conclusion, sanitary prevention and control options are very limited, prophylactic vaccination is the most 
realistic option for long-term prevention and control of NDV.  Source reduction is possible with vaccination by 
reducing the amount of circulating virus in the population and in the environment.  Elimination is not possible 
since NDV of different pathotypes remain endemic throughout the inhabited world, including the developed 
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Given the challenges of sanitary measure discussed above, medical prophylaxis using vaccination will permit 
pathogen reduction and control.  Below are typical NDV vaccination program schedules using traditional live 
attenuated and inactivated oil emulsion vaccines that are tailored to control the circulating challenge field 
genotype and pathotype. 
 
NDV strains used in conventional commercial live virus vaccines fall into two groups [3][27]:  
• Lentogenic vaccines, such as Hitchner-B1, La Sota, V4, NDW, I-2, F – Priming dose (or booster dose)  
• Mesogenic vaccines, such as Roakin, Mukteswar and Komarov – Prime or booster dose.  
 
Vaccine master seed virus strains should not have an intracerebral pathogenicity index ICPI exceeding 0.4.  
Examples of vaccine use in low risk and high situations are depicted in Figure 11 [2]. 
 
Example protocol when NDV field pathotype is mild or sporadic: 
• Live La Sota by conjunctival (eye drop) or spray administration at 1 day of age;  
• Live Hitchner-B1 or La Sota at 18–21 days of age in the drinking water;  
• Live La Sota in the drinking water at 10 weeks of age; and  
• Inactivated oil emulsion vaccine at point of lay.  
 
Example protocol when NDV field pathotype is severe or endemic: 
• Live La Sota by conjunctival or spray administration at 1 day of age;  
• Live Hitchner-B1 or La Sota at 18–21 days of age in the drinking water;  
• Revaccination at 35–42 days of age with live La Sota in the drinking water or as an aerosol;  
• Repeat at 10 weeks of age with an inactivated vaccine (or a mesogenic live vaccine); and  
• Repeat at point of lay.  
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Figure 11: Summary of the live NDV vaccine strains [26] 
 
The level of (blocking) maternal antibodies is important to consider when vaccinating progeny.  Route of 
administration and adjuvant are also very important to achieve both the level of safety and efficacy needed to 
protect the flock from field challenge. Post-vaccination seromonitoring using the ELISA or HI test is always 
advised and periodic challenge tests may be required to make adjustments to the prevailing genotype. Live 
attenuated vaccines have the potential to increase in pathogenicity when incomplete flock immunity occurs due 
to inadequate vaccination technique [1][2]. 
 
Options and Strategies for Vaccination 
A realistic objective for a sustainable smallholder poultry vaccination program is to control (manage) NDV rather 
than attempt to eliminate the virus since: 1) Lentogenic NDV are ubiquitous; 2) Mesogenic NDV are endemic in 
many African and Asian countries; 3) biosecurity options are limited; and 4) vaccination achieves reduction in 
shedding but does not produce sterilizing immunity [1][2][3][26].  Categories of NDV vaccines available, their 
advantages and example are summarized in Table 11. 
Alders and Pym offer five recommendations for sustainable NDV vaccination programs poultry smallholders [20]. 
• An appropriate vaccine, vaccine technology and vaccine distribution mechanisms;  
• Effective extension materials and methodologies that target veterinary and extension staff as well as 
community vaccinators and farmers;  
• Simple evaluation and monitoring systems of both technical and socio-economic indicators;  
• Economic sustainability based on the commercialization of the vaccine and vaccination services and the 
marketing of surplus chickens and eggs, and  
• Support and coordination by relevant government agencies for the promotion of vaccination programs.  
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Important strategic considerations for selecting an appropriate NDV vaccine are summarized below: 
1. Simple to apply in communities based on needs and capacities of the communities and the technical 
resources of the government. 
2. Fit for purpose – Monovalent vaccines are more cost effective and targeted for specific needs to control 
NDV for smallholder populations.  However, in some situations bivalent or multivalent choices may be 
needed to control other diseases, depending on cost.  Vaccine administered via eye drop is more likely 
to result in owner compliance since it is simple to perform, non-invasive and is does not cause adverse 
tissue reactions [20][27].  
3. Epidemiologically appropriate – Possible reversion of live lentogenic or mesogenic strains used to 
vaccinate commercial poultry should be considered when planning a smallholder vaccination program 
[1][20]. 
4. Ability to license vaccine – Some countries such as Indonesia does not permit the use of genetically 
modified recombinant vaccines [28]. 
5. Antigenically appropriate – Seromonitoring and challenge studies inform vaccine choice based on 
genotype [1][14]. 
6. Thermostability – I-2 vaccine and other similar vaccines allow flexibility to increase the efficiency and 
uniformity of poultry immunization [27]. 
7. Broad age-based application in multi-age flocks typical of village smallholder flocks [27]. 
8. Use of multivalent vaccines may be a scientifically valid approach to take when it is possible.  The reality 
in the field is that many economically significant poultry diseases are neither reported nor assessed 
quantitatively, particularly NDV. Vaccine cost as well as farmer and government perception of risk must 
be carefully assessed in order to prioritize resources for sustainable, self-directed vaccination programs. 
Needs assessments of the primary stakeholders should first be conducted prior to embarking on 
prevention and control through vaccination. In this way, vaccination, biosecurity training and 
surveillance systems incorporated specific measures for priority diseases as well as NDV.  The use of 
NDV-AI vaccines can be considered depending on the results of an epidemiological risk assessment. 
 
 
I-2 is the first Thermostable NDV vaccine developed and is well suited for use with smallholder poultry 
populations [29][30].   Important characteristics favouring its use follow: 
• Thermostable for 8 weeks at 28°C when in freeze-dried form and stored in the dark;  
• A minimum of 106 EID50/bird is required to produce adequate protection; 
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• Can be administered via eye drop, drinking water, certain feeds and injection  
• Eye drop administration of the vaccine produced a greater survival rate, had a lower frequency of 
administration and was easy; 
• Confirm that the eye-dropper to be used is made of virus- friendly plastic and that it be calibrated to 
ensure that one drop contains one dose;  
• The same dose is given to birds of all ages, from day 1 to adults  
• I-2 ND vaccine spreads from vaccinated to unvaccinated birds when housed together  
• Safe to both bird and handler. It produces no evidence of clinical respiratory signs, weight loss, mortality 
in young chickens or egg production drop  
• 80% protection in the field in the face of an outbreak, when given every 4 months via eye drop.  
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(yes/no) (yes/no) (yes/no) 
Country       Compulsor
y 
vaccination 
Who pays for the 
vaccine? 
Who delivers 





















         
Ethiopia 
         
Ivory Coast OUI PASSIF MAIS 









Kenya yes Yes, passive no no farmers both poultry yes yes 
Madagascar 
         
Malawi YES YES 
(PASSIVE/ACTIV
E) 
YES YES COMBINATION BOTH 
OFFICIAL 
AND PRIVATE 
POULTRY N/A N/A 
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Mali Yes Yes, passive Yes Yes COMBINATION Both poultry No No 
Mozambique 
         
Rwanda Yes Both Yes Yes Farmers Official Poultry No No 
Senegal 
         
South Africa 
         







both Poultry no no 




Zambia Yes Yes - passive Yes Yes Combination Both Poultry No No 
Bangladesh Yes Yes (Passive) Partial No Combination (1) 








Poultry  No Yes 
India 
         
Nepal No yes/passive No No combination both poultry N/A N/A 
Indonesia 
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Myanmar yes yes(passive) no no Government, 
Farmers 
Both poultry no yes 
Vietnam Yes Yes/Passive No Yes Farmers Both Poultry No Yes 
1Surveillance: is the systematic on-going collection, collation and analysis of data and the timely dissemination of information to those who need 
to know so that action can be taken.  
2Control: a programme which is approved and managed or supervised by the Veterinary Authority of a country for the purpose of controlling a 
vector, pathogen or disease by specific measures applied throughout that country, or within a zone or compartment of that country. 
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Table 12: Currently available categories of NDV vaccines available, their modality of action and examples of 
vaccine formulations [1][2][3][26] 
 
Category Modality of Action Example Vaccine Formulations 
DNA vector vaccines Carrier virus expressing one or more 
immunogenic NDV proteins (usually F and/or 
HN) induces an immune response against both 
NDV and the vector virus itself  
Vaccinia virus (Meulemans, 1988), Fowlpox 
virus (Boursnell et al., 1990; Karaca et al., 
1998; Olabode et al., 2010), Pigeonpox virus 
(Letellier et al., 1991), Herpesvirus of 
turkeys (Heckert et al., 1996; Morgan et al., 
1992; Reddy et al., 1996), Marek’s disease 
virus (Sakaguchi et al., 1998) and avian 
adeno-associated virus (Perozo et al., 2008)  
Subunit vaccines Expression of NDV proteins (usually F and/or 
HN) 
Baculovirus vectors (Fukanoki et al., 2001; 
Lee et al., 2008; Mori et al., 1994; Nagy et 
al., 1991) or plants (Berinstein et al., 2005; 
Yang et al., 2007)  
DNA vaccines, (plasmid)  
 
DNA encoding relevant immunogenic NDV 
proteins 
(Loke et al., 2005; Rajawat et al., 2008). 
Reverse genetics 
vaccines 
Modify the NDV genome and to develop NDV 
strains with new properties  
Serological differentiation (DIVA vaccines 
(Mebatsion et al., 2002; Peeters et al., 
2001) and the incorporation and expression 
of foreign genes, thereby making NDV itself 
a vaccine vector for application in poultry 
(Nakaya et al., 2001; 2010; Schroer et al., 
2009; Steel et al., 2008) and other species, 
including primates (Dinapoli et al., 2007).  
Newcastle Disease | Monograph 01 






Category Modality of Action Example Vaccine Formulations 
Live attenuated Conventional egg passage attenuation ICPI < 
0.4; live virus vaccines administered to birds 
by incorporation in the drinking water, 
delivered  
as a coarse spray (aerosol), or by intranasal or 
conjunctival instillation; some mesogenic  
strains are given by wing-web intradermal 
inoculation  
Both thermostable heat tolerant selected 
Australian virus, strain I-2 isolated about 
1990; live thermostabilised vaccine with 
D58 isolate from India; conventional 




Inactivated virus prepared from allantoic fluid 
inactivated by the addition of formaldehyde 
or beta-propiolactone in oil emulsion; tend to 
be more expensive than live vaccines; 
application entails handling and injecting 
individual birds; administered intramuscularly 
or subcutaneously; each bird thus receives a 
standard dose; advantage of no subsequent 
spread of virus or adverse respiratory 
reactions; virulent and avirulent strains are 
used as seed virus; from a safety control 
perspective the use of the latter appears more 
suitable; much larger amount of antigen is 
required for immunization than for live virus 
vaccination  
(no virus multiplication) 
Many commercial formulations (e.g. 
Intervet, Laprovet) 
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Commercial vaccines manufactured in Africa and Asia  
 
Presented in Table 13 below is a list of vaccines licensed in the 20 selected countries is presented.  Over 522 vaccines were reviewed. 
 
Table 13: Commercial NDV vaccines manufactured in Africa and Asia. 
 
Specific Vaccines and Formulation 
AVI ND La Sota, water based delivery; 
Laprovet, Evervictory Ltd, Uganda.  
*Avivax F Kenya Agricultural Research Institute [KARI]; F Type, La Sota strain; 0.1 ml/dose 
Bio-Vac B1, Fatro, Italy (registered in Myanmar); 0.1 ml/dose 
F Strain Indovax Private Ltd. India;  
GlobiVac ND C131 Globion India Private Ltd.; 1 dose contains min. 106 EID 50 ND virus, Strain clone 13-1 
*I2VAX Laboratoire National Vétérinaire [LANAVET]; Cameroon 
*Kukustar vaccine Brentec Vaccines Limited Uganda; I2 thermostable vaccine; 
La Sota Strain Indovax Private Ltd. India 
Live B1 Hester Biosciences Ltd. India; Live attenuated; Intraocular, Intranasal, Subcutaneous, Oral, Drop eye 
MEDIVAC ND CLONE-45 Medion Farma Jaya Indonesia; one dose (contains at least 107 EID50 ND virus) per chicken 
MEDIVAC ND HITCHNER B1 45 Medion Farma Jaya Indonesia; 
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Specific Vaccines and Formulation 
Mild Living Vaccine of Newcastle Disease (Clone-30 Strain) in oil emulsion; Qingdao Yebio Bioengineering Co. Ltd.  China; 0.05 ml  
*HB1, La Sota, thermostable-I2; Newcastle Disease National Veterinary Institute of Ethiopia; 
Newcastle Disease Vaccine Living (La Sota Strain) B.P. (Vet.) Ventri Biologicals [Venkateshwara Hatcheries Private Ltd.] India 
Ranikhet disease Vaccine F Institute of Animal Health and Veterinary Biologicals [Kerala]; India; *Chicks at one day of age.  
*Ranikhet Disease Vaccine, Live, Lentogenic "F" Strain, I.P. (Vet.) BiO-MED Private Ltd.; Intranasal, intraocular, Oral, eye drop  
*TAbic V.H. Clone (Tablet vaccine) Phibro Vaccines [ABIC Biological Laboratories] Spray method, Oral, Intraocular, eye drop; V.H. Clone, Lyophilized live 
vaccine in vials (Israel, Myanmar) 
*TEMEVAC, Thermo-tolerant Newcastle Disease Vaccine Strain I-2 Tanzania Veterinary Laboratory Agency; Ocular 
 
V.H. Phibro Vaccines [ABIC Biological Laboratories] India, Israel; Spray method, Oral, Drop eye, Intraocular 
Vaksimune Clone, Vaksindo, Indonesia; ND Clone Spray method, Oral, Intraocular, Drop eye 
Vaksimune NDHV; Vaksindo, Indonesia; Live Ulster attenuated 
AVIVAC ND DELTAMUNE (Pty), Ltd. South Africa; Killed oil emulsion 0.5 ml/dose 
Cevac Broiler ND K; Ceva Sante Animale; Oil emulsion 0.1 ml/dose (China, Indonesia, South Africa) 
Encivax Indovax Private Ltd.  India; Killed oil emulsion 0.5 ml/dose subcutaneous, intramuscular 
GlobiVac NDK Globion India Private Ltd. India; Killed oil emulsion 0.5 ml/dose subcutaneous, intramuscular 
Imopest (Gallimune ND)  MCI Sante Animale [Merial] Ulster 2c Strain; Killed inactivated in oil emulsion; 0.3ml intramuscular injection; (China, Myanmar) 
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Specific Vaccines and Formulation 
Inactivated Chick-ND Hester Biosciences Ltd. India; 0.5 ml subcutaneous; Formulated for chicks from 1-10 days of age.  
ITA-NEW Laprovet, France, Uganda; 0.2-0.5 ml/dose subcutaneous or intramuscular; Additional information from Evervictory Ltd, Uganda  
Jova Zeit 1,7 Jordan Bio-Industries Center (JOVAC) (Jordan, Ethiopia) Bivalent Killed ND/AI vaccine La Sota and H9N2 
MEDIVAC ND-AI Emulsion Medion Farma Jaya Indonesia; Killed La Sota and H5 in oil emulsion; 0.2 ml per young chicken or 0.5 ml per adult chicken.  
Mukteshwar Strain (R2B) Indovax Private Ltd. India; 0.5 ml/dose intramuscular or subcutaneous 
Nectiv Phibro Vaccines [ABIC Biological Laboratories] Israel. (Licensed in India); V.H. strain; Chickens and turkeys. Dosage: 7-21 old chicks 0.3 ml; 21 day old 
chicks and older 0.5 ml. Oil emulsion. 
Newcastle Disease Vaccine Living (R2B Strain) B.P. (Vet.) Ventri Biologicals [Venkateshwara Hatcheries Private Ltd.] India; oil emulsion; 0.5ml Intramuscular, 
Subcutaneous 
newcastle influenza Avimex S.A. de C.V.; H5N2 La Sota mineral oil emulsion; 0.05 ml/dose subcutaneous (Mexico, Indonesia) 
Nobivac ND Broiler MSD Animal Health [Intervet, Schering-Plough Animal Health, Merck Sharp & Dohme, Coopers Animal Health]; Killed oil emulsion; 0.1 
ml/dose intramuscular subcutaneous in day old chicks 
OL-VAC Fatro Italy, Myanmar; Mineral oil 0.5 ml/dose; Vaccination scheme: first dose at 18-20 days and second at 18-20 weeks. 
*Vaksimune ND L Inaktif Vaksindo; Indonesia; Genotype VII, strain N018; oil emulsion 
Newcastle disease, avian flu combined vaccine (H9,F strain, Lo Sota) [killed] Merial China subcutaneous injection from neck 
Newcastle disease, avian flu combined vaccine (rLH5-6 strain) [live] Weke Biotechnology (the vaccine company supported by Harbin Veterinary Research 
Institute); 0.05ml nose drops or eye drops for each chicken and 0.2ml I.M. for each one 
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Commercial vaccines imported into Africa and Asia  
 
Table 14: Newcastle disease commercial vaccines imported into Africa and Asia and the number of doses used annually 2012-2015 




Doses Imported  Doses Imported Doses Imported Doses Imported 
2015 2014 2013 2012 
Burkina Faso 
       
Ethiopia 
       
Ivory Coast Avi Nd La Sota+Ib 
 
Hongrie 25 000 000 




France 605 000 




Espagne 400 000 




Hongrie 650 000 




Hongrie 7 000 000 
   
 
Gallimune Nd E 
 
France 10 000 000 




France 26 000 




Espagne 1 500 000 
   
 
Hipraviar Clon H120 
 
Espagne 1 200 000 




France 700 000 




Espagne 5 000 000 
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Doses Imported  Doses Imported Doses Imported Doses Imported 




Italie 600 000 




Hongrie 2 000 000 
   
 
Izovac Hitchner B1 La 
Sota 
 
Bresil/Italie 30 000 000 
   
Kenya 
   
N/A N/A N/A N/A 
Madagascar 
       
Malawi  Lasota   Live 
Attenuated  
 Rsa  3,600,000  3,000,000  2,600,000  2,750,000  
 
 Hitchner   Live 
Attenuated  
 Rsa  1,500,000  150,000  1,700,000  1,200,000  
Mali Itanew; B8l; Ceva Newl; 
Cevaunil; Imopest; 






21,900,000 21,200,000 19,800,000 20,000,000 
Mozambique 
       
Rwanda 
  
Belgium 2,210,000 1,800,000 1,500,000 
 
Senegal 
       
South Africa 
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Doses Imported  Doses Imported Doses Imported Doses Imported 
2015 2014 2013 2012 
Tanzania 
 










Various 63,906,000  82,963,000  11,550,000  26,083,000  
  




48,000  75,000  30,000  10,000  






 2,100,000   -     3,100,000  NA 
 
NA 6/10 Republic Of 
South Africa 
 NA   81,000   NA  NA 
 






























Spain  100,000  
  
NA 
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Doses Imported  Doses Imported Doses Imported Doses Imported 




USA  500,000  
   
 
NA C131 Republic Of 
South Africa 




NA Clone 30 Republic Of 
South Africa 




NA VH Republic Of 
South Africa 








 100,000  






 64,000  























India  100,000  
   
Bangladesh Lasota Vaccine Lasota Strain 126,660,000 77,315,000 110,630,000 146,681,000 
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Doses Imported  Doses Imported Doses Imported Doses Imported 
2015 2014 2013 2012 
 
ND Vaccine Live And 
Killed(B1/F) 
173,180,000 507,000,000 383,700,000 488,000,000 
 
India 
       




France 1,000,000 700,000 350,000 105,000 
 
Biovac Lasota Lasota  Italy 1,200,000 840,000 420,000 126,000 
 
Biovac Lasota H120 Lasota & 
Massachuset
ts H120 
Italy 1,320,000 924,000 462,000 138,600 
 
Biovac NDV 6/10 NDV 6/10 Of 
ND Virus 
Italy 1,000,000 700,000 350,000 105,000 
 
Bronki -L Mass 
H120+Lasota 
India 1,600,000 1,120,000 224,000 33,600 
 
DS ND-IB B1 H120 Korea 9,000,000 6,300,000 3,150,000 945,000 
 
Encivax Lasota India 200,000 140,000 28,000 4,200 
 




Italy 500,000 350,000 175,000 52,500 
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Doses Imported  Doses Imported Doses Imported Doses Imported 






H120+B1 Korea 4,000,000 2,800,000 1,400,000 420,000 
 
Himmvac Lasota Lasota Korea 11,075,000 7,752,500 3,876,250 1,162,875 
 
Himmvac ND+IB Lasota H120 Korea 4,534 3,174 1,587 476 
 
IB -Olvac Lasota+ 
Massachuset
ts M41 
Italy 225,000 157,500 78,750 23,625 
 
IB+Lasota ND Lasota & 
Mass Type 





India 600,000 420,000 84,000 12,600 
 
IBD Plus Intermediate 
Plus 
India 17,000,000 11,900,000 2,380,000 357,000 
 
IZO Vac  Lasota Lasota Italy 2,000,000 1,400,000 700,000 210,000 
 
IZO Vac  ND-IB Lasota+ 
W2512 
Italy 600,000 420,000 210,000 63,000 
 
IZO Vac 120 Clone Lasota Italy 1,800,000 1,260,000 630,000 189,000 
Newcastle Disease | Monograph 01 










Doses Imported  Doses Imported Doses Imported Doses Imported 
2015 2014 2013 2012 
 
IZO Vac 120-Lasota Lasota, 
Madachuset
ts 
Italy 15,000,000 10,500,000 5,250,000 1,575,000 
 
IZO Vac B1 B1 Italy 600,000 420,000 210,000 63,000 
 







Italy 1,200,000 840,000 420,000 126,000 
 
IZOVAC B1 B1 Italy 1,000,000 700,000 350,000 105,000 
 
Izovac IB H120 Massachuset
ts 
Italy 1,000,000 700,000 350,000 105,000 
 
Izovac Lasota Lasota  Italy 1,500,000 1,050,000 525,000 157,500 
 




India 100,000 70,000 14,000 2,100 
 
ND B1 Lentogenic 
B1 
India 7,700,000 5,390,000 1,078,000 161,700 
 
ND B1+IB ND B1 Strain 
& Mass Type 
India 100,000 70,000 14,000 2,100 
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Doses Imported  Doses Imported Doses Imported Doses Imported 
2015 2014 2013 2012 
 
ND IBD  Lentogenic 
Lasota 
Lukert Type 
India 2,040,000 1,428,000 285,600 42,840 
 







Singapore 300,000 210,000 105,000 31,500 
 
Nectiv Forte VH Clone Israel 500,000 350,000 175,000 52,500 
 
New Castle Bron Mass Lasota IB 
Massachuset
ts (M41) 
Singapore 1,800,000 1,260,000 630,000 189,000 
 




India 75,000 52,500 10,500 1,575 
 
Newcastle Disease Vac. Lentogenic 
Lasota 
India 2,760,000 1,932,000 386,400 57,960 
 
Newcastle Lasota+ 
Bron Mass Vac 
Lasota IB+M-
41 
Korea 1,000,000 700,000 350,000 105,000 
 
Nobilis IB+ND Inactivated 





144,000 100,800 50,400 15,120 
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Doses Imported  Doses Imported Doses Imported Doses Imported 
2015 2014 2013 2012 
 




6,400,000 4,480,000 2,240,000 672,000 
 
Nobilis ND Clone 30 ND Clone 30 The 
Netherlands 
1,000,000 700,000 350,000 105,000 
 
Nobilis ND Clone 30 ND Clone 30 The 
Netherlands 
1,000,000 700,000 350,000 105,000 
 
Nobilis ND Clone 30 ND Clone 30 The 
Netherlands 
500,000 350,000 175,000 52,500 
 
Nobilis ND Clone 30 ND Clone 30 The 
Netherlands 
1,000,000 700,000 350,000 105,000 
 
Nobilis ND Lasota ND Lasota The 
Netherlands 
300,000 210,000 105,000 31,500 
 
Nobilis ND Lasota ND Lasota The 
Netherlands 
500,000 350,000 175,000 52,500 
 
Nobilis ND Lasota Lasota The 
Netherlands 
250,000 175,000 87,500 26,250 
 
Nobilis ND Lasota Lasota The 
Netherlands 
250,000 175,000 87,500 26,250 
 
Nobilis ND Lasota Lasota The 
Netherlands 
300,000 210,000 105,000 31,500 
Newcastle Disease | Monograph 01 










Doses Imported  Doses Imported Doses Imported Doses Imported 
2015 2014 2013 2012 
 
Nobilis ND Lasota ND Lasota The 
Netherlands 
1,000,000 700,000 350,000 105,000 
 
Nobilis Newcavac Inactivated  
ND Clone 30 
The 
Netherlands 
12,000 8,400 4,200 1,260 
 
Nobilis Newcavac Inactivated  
ND Clone 30 
The 
Netherlands 
60,000 42,000 21,000 6,300 
 
Nobilis Newcavac Inactivated  
ND Clone 30 
The 
Netherlands 
60,000 42,000 21,000 6,300 
 






1733 & 2408 
The 
Netherlands 
92,000 64,400 32,200 9,660 
 
OL Vac  Lasota Of 
ND Virus 
Italy 54,000 37,800 18,900 5,670 
 




Italy 18,000 12,600 6,300 1,890 
 
Olvac A+B+G ND Lasota,IB 
M41,IBD 
Italy 18,000 12,600 6,300 1,890 
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Doses Imported  Doses Imported Doses Imported Doses Imported 








Italy 18,000 12,600 6,300 1,890 
 





Italy 18,000 12,600 6,300 1,890 
 




1133 Of Reo 
Virus 
Italy 1,500,000 1,050,000 525,000 157,500 
 
Poulshot  Lasota Newcastle 
Lasota 
Korea 500,000 350,000 175,000 52,500 
 
Poulshot  Lasota+IB Lasota+ IB 
H120 
Korea 1,000,000 700,000 350,000 105,000 
 
Poulshot Gumboro Intermediate 
LZD 288 
JAC3 
Korea 1,000,000 700,000 350,000 105,000 
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Doses Imported  Doses Imported Doses Imported Doses Imported 
2015 2014 2013 2012 
 





Korea 100,000 70,000 35,000 10,500 
 
Poulshot Lasota  Lasota Korea 500,000 350,000 175,000 52,500 
 
Poulshot Lasota+IB Lasota +IB 
H120 
Korea 1,000,000 700,000 350,000 105,000 
 
Poulvac N+B Lasota IB 
Massachuset
ts (M41) 
Singapore 30,000 21,000 10,500 3,150 
 
Poulvac N+B Vac Lasotaib 
Massachuset
ts (M41) 
Singapore 20,000 14,000 7,000 2,100 
 
Poulvac N+B Vac Lasotaib 
Massachuset
ts (M41) 
Singapore 30,000 21,000 10,500 3,150 
 
Poulvac N+B Vac Lasotaib 
Massachuset
ts (M41) 
Singapore 30,000 21,000 10,500 3,150 
 
Poulvaci N+B  ND Lasota & 
Bronchitis 
Mass 
Singapore 200,000 140,000 70,000 21,000 
Newcastle Disease | Monograph 01 










Doses Imported  Doses Imported Doses Imported Doses Imported 
2015 2014 2013 2012 
 
Pro Vac IBD VMG 91 Singapore 800,000 560,000 280,000 84,000 
 
Pro Vac IBD VMG 91 Singapore 3,500,000 2,450,000 1,225,000 367,500 
 
Pro Vac ND IB Hitchner 
B1,IB H120 
Singapore 1,000,000 700,000 350,000 105,000 
 
Pro Vac ND IB Hitchner 
B1,IB H120 
Singapore 1,000,000 700,000 350,000 105,000 
 
Pro Vac ND Lasota Lasota Singapore 850,000 595,000 297,500 89,250 
 
Pro Vac ND Lasota Lasota  Singapore 3,500,000 2,450,000 1,225,000 367,500 
 
Pro Vac ND Lasota Lasota Singapore 800,000 560,000 280,000 84,000 
 
Pro Vac ND Lasota Lasota  Singapore 2,000,000 1,400,000 700,000 210,000 
 
Quadractin  (VH+IB 
M41+MB+Re
o S1133 
Israel 2,000,000 1,400,000 700,000 210,000 
 





India 500,000 350,000 70,000 10,500 
 
R2B Mukteshwor India 40,000 28,000 5,600 840 
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Doses Imported  Doses Imported Doses Imported Doses Imported 
2015 2014 2013 2012 
 
R2B Mukteshwor India 400,000 280,000 56,000 8,400 
 
R2B Mukteshwor India 80,000 56,000 11,200 1,680 
 
R2B Mukteshwor India 400,000 280,000 56,000 8,400 
 
R2B Mukteshwor India 200,000 140,000 28,000 4,200 
 
Ranikhet Lasota India 17,000,000 11,900,000 2,380,000 357,000 
 
Ranikhet  With Diluent Lentogenic F 
I.P. 
India 130,000 91,000 18,200 2,730 
 
Ranikhet F Strain F Strain India 36,500,000 25,550,000 5,110,000 766,500 
 
VH VH Clone 
(Lentogenic) 
Israel 800,000 560,000 280,000 84,000 
 
VH+ H120 VH+ H120 Israel 4,000,000 2,800,000 1,400,000 420,000 
 
Vir- 116 ND Lasota Lasota Israel 3,200,000 2,240,000 1,120,000 336,000 
 
Vir-106 –ND B1  Hitchner B1 Israel 13,640,000 9,548,000 4,774,000 1,432,200 
 
Virsin-116 ND Lasota Lasota Israel 2,500,000 1,750,000 875,000 262,500 
 
Vol Vac IBH+ND Adino Virus 
Type 4+ 
Lasota 
Germany 2,500,000 1,750,000 875,000 262,500 
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Doses Imported  Doses Imported Doses Imported Doses Imported 
2015 2014 2013 2012 
   
Totals 816,058,534 162,220,474 58,792,487 15,405,971 
Indonesia 
       

































ls Sdn. Bhd 
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Doses Imported  Doses Imported Doses Imported Doses Imported 
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The strategic objectives for an ideal vaccine and vaccination program include the following: 
1. Live prime dose that is safe and non-reverting to virulent form after it has circulated in live poultry; 
2. Thermostable for ease of use in smallholder setting; 
3. Protective, long-lasting immunity resulting in reduced replication and transmission on a population 
basis; 
4. Vaccine is matched with the genotype of circulating field strains, ideally using reverse genetics 
technology [8][14]; 
5. Can be delivered easily using simple and attainable field logistics; 
6. Rapid onset and long duration of immunity; 
7. Potential combination as part of a multivalent vaccine with other priority diseases for smallholders such 
as IBD based on country needs assessments. 
 
Table 15: Target product profile. 
 
Attribute Minimum (currently available 
vaccine) 
Ideal 
Antigen Standard replicating lentogenic B1, 
La Sota, Ulster, F, Clone line 
Non-replicating reverse genetics 
engineered for field strain based on 
genotype of field strain 
Indication for use Prevention and control of NDV Reduced replication and shedding of NDV 
Recommended species Chickens, turkeys, pigeons Primarily chickens  
Recommended dose Range of 0.05 ml by topical 
application (live attenuated) to 0.5 
for injectable 
0.05 ml by topical application 
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Pharmaceutical form Antigenic as La Sota strain but mild 
as B1 of Newcastle Disease virus 
field strain and pathotype 
Thermostable, reverse genetics engineered 
La Sota or similar strain 
Route of administration Topical and injectable Topical for ease of application 
Regimen – primary vaccination Topical preferable to injectable  Day old chick 
Regimen – booster Killed vaccine follows live prime 
dose at one day of age 
4-6 months ideally based on village flock 
serological profile results 
Epidemiological relevance and use 
for smallholders 
Limited to live attenuated 
thermostable vaccines 
Both live attenuated and reverse genetics 
thermostable vaccines 
Recommended age at first 
vaccination 
Day old chick or up to 3 weeks of 
age 
Day old chicks 
Onset of immunity 10 days (live) - 21 days (killed) 7 days ideally 
Duration of immunity Range of 3 weeks (live prime) to 4 
months (booster); 
4-6 months 
Expected efficacy 65-85% field Minimum of 80% within-flock (villages) 
protection; 90% among flocks (villages) 
Expected safety 80% 99% 
Withdrawal period 21-42 days Less than 21 days 
Special requirements for animals Live attenuated – vaccinate all 
flock members to avoid reversion 
to virulence in unvaccinated 
poultry; Killed – injection tissue 
granulomas 
Safe with no granulomas to remove as 
disincentive to vaccinate 
Special requirements for persons Live attenuated – prevent 
conjunctivitis in vaccine and 
poultry handlers 
Killed – tissue reaction or 
anaphylaxis 
Safe and non-reactive 
Package size 100-5,000 doses per bottle 100-500 doses per bottle 
Price to end user $0.04-$0.1 $0.01 - $0.05 
Storage condition and shelf-life as 
packages for sale 
Thermo-intolerant: Keep in cool 
dark place 2-8 degrees centigrade 
Thermo-tolerant for 8 weeks 
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Thermo-tolerant: 3-8 weeks away 
from ultraviolet light 
In-use stability Live – unstable and mix with non-
chlorinated water 
Killed – greater stability under 
proper storage and timely 
administration – prevent bacterial 
contamination 
Live/Killed – unstable 





Key Conclusions Related to Vaccination 
Short-term Solutions:  Live, attenuated and killed, inactivated NDV vaccines are effective, and can produce 
protective titers when applied properly. The first approach would be to 1) improve disease detection using rapid 
test kits; 2) improve reporting; 3) and optimize the access and delivery of vaccines in the field since it is a limiting 
gap regardless of the vaccine that is used.  Thermostable vaccines currently are closest to the ideal vaccine for 
use in smallholder poultry. Proper delivery of vaccine to smallholder with community engagement is a key gap 
to overcome logistical challenges for the safe and effective delivery of vaccine. 
Medium-term Solutions: 1) The further development of reverse genetics vaccines antigenically matched with the 
field strain genotype will optimize the immune response (level and duration of immunity) in typical currently 
available vaccine strains. Investment in the collection and molecular analysis of country-specific field strains will 
be required. 2) Improvement in diagnostic tests in vitro (cell culture) and rapid tests in the field will also be 
needed. 
Long-term Solutions: There are two main needs: 1) Further refinement of a vaccination model multivalent, non-
replicating, antigenically matched and epidemiologically appropriate; 2) Development of breed lines of native 
poultry with high levels of innate genetic resistance to further reduce replication and to increase vaccine 
efficacy.  Needs assessments are recommended to assess the need for a multivalent NDV vaccine in combination 
with infectious bursal disease (IBD) vaccine or other priority poultry disease, which also result in significant 
losses in some regions. 
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This monograph uses an evidence-based approach consulting primary referenced studies which summarize key 
points and considerations for undertaking successful vaccine development.  Reporting bias presents a significant 
handicap for estimating country-based risk for Newcastle disease as explained under section 3.  Reporting bias is 
due to: 1) habituation of poultry owners to the regular and persistent losses due to NDV since farmers 
themselves have learned to “live with” the disease; 2) lack of capacity and transparency from government 
officials; 3) lack of incentive to report (no compensation paid).  It is common for village poultry owners to eat 
recently dead or sick poultry due to food scarcity.  Community engagement is therefore a critical consideration 
for any vaccination initiative.  In addition, the prevalence studies are likely more useful to develop vaccination 
strategies, however they must be evaluated carefully.  Study design greatly affects the interpretation of the 
results and how to best apply the results for future vaccination planning and delivery.   
Gaps in knowledge or capacity impacting strategic planning and effective implementation. The following gaps 
are highlighted in relation to vaccine development and sustainable field implementation of vaccination for 
Newcastle disease: 
1. Lack of accurate information on reservoirs as well as NDV incidence and prevalence from farmers, 
including epidemiologically related semi-intensive poultry producers and the government services; 
2. Limited genotype characterization of country-specific field strains of NDV. 
3. Need for field based rapid test kits to detect the field strains since no field-based test kits are currently 
available;  
4. Need to replace the SPF chicken challenge-based model with a cell line culture model in developing 
countries with laboratories lacking BSL-3 required to conduct challenge studies safely; 
5. Systematic delivery and monitoring of vaccine use so that it is applied uniformly among members of 
smallholder village flocks.  Interestingly, Dr. David Suarez indicated that in Tanzania, as the availability of 
I-2 vaccine decreased due to high demand, the vaccine distributors and vaccinators began diluting the 
vaccine while charging the same price.  Results suffered, and owner compliance also declined. Thus, an 
effective monitoring program of vaccine use is needed to avoid these issues;   
6. Wider application of safe, non-replicating NDV vaccines at the interface of commercial and smallholder 
sectors where spillover can occur. 
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